



This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Organised by Sahlgrenska Academy,
University of Gothenburg, Sweden

Course Director:
Assoc Professor Björn Dahlöf



Sahlgrenska Academy
UNIVERSITY OF GOTHENBURG

EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2008

CARDIOVASCULAR RISK management and ATHEROSCLEROSIS:

new insights for improving the management of cardiovascular disease

CHAIRPERSONS

Philip Barter

The Heart Institute
Sydney, Australia

Leif Erhardt

Lund University
Lund, Sweden

FACULTY

Christie Ballantyne

Baylor College of Medicine, Section of Atherosclerosis
Houston, Texas, USA

Michiel Bots

Julius Centre Health Sciences and Primary Care
Utrecht, The Netherlands

Wolfgang Koenig

University of Ulm Medical School
Ulm, Germany

Tuesday **2 September** 2008

14.00–15.30

Room Stockholm Zone B1

Supported by an unrestricted educational grant from AstraZeneca

In compliance with EBAC/EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

AstraZeneca
CARDIOVASCULAR

PROGRAMME

Cardiovascular risk management today:

how far have we come?

Leif Erhardt

Imaging techniques:

how important are they in the management of atherosclerosis?

Michiel Bots

Atherosclerotic plaque:

emerging evidence with statin therapy

Christie Ballantyne

Looking beyond traditional lipid measurements:

emerging biomarkers

Wolfgang Koenig

Translating evidence

into meaningful clinical benefits

Philip Barter

LEARNING OBJECTIVES

At the end of this programme, participants should:

- recognise the need for early diagnosis and effective, comprehensive management of dyslipidaemia in patients at increased risk of cardiovascular disease
- understand the advantages and benefits of different vascular imaging techniques
- describe recent evidence showing the effects of intensive statin therapy on atherosclerosis
- evaluate emerging markers of risk and their potential future role in the management of cardiovascular disease